{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:38:19Z","timestamp":1777941499490,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Optic neuritis (ON) has been considered to be an important factor in the diagnosis of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), making ON detection increasingly critical for early diagnosis. Furthermore, subclinical ONs presenting no distinct decrease in visual acuity can be missed. Low contrast visual acuity (LC-VA) is known to be able to capture visual loss not seen in conventional high-contrast visual acuity (HC-VA) in MS. Therefore, to increase the sensitivity of ON detection, we investigated the advantage of LC-VA over conventional HC-VA. One hundred and eight patients with demyelinating disease (35 MS, 73 NMOSD) with ON at least 3 months prior and 35 controls underwent neuro-ophthalmic evaluation, including best-corrected conventional high contrast visual acuity (HC-VA) and 2.5% and 1.25% low contrast visual acuity (LC-VA). Receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) of various visual functions were used to determine the most relevant visual function test for the detection of optic nerve involvement. Additionally, the optimal cutoff point was obtained from the Youden index (J-index) as the points with the best sensitivity-specificity balance. When distinguishing ON from non-ON, the area under the ROC curve (AUC) was highest for the 2.5% LC-VA (0.835, <jats:italic>P<\/jats:italic> &amp;lt; 0.001; sensitivity 71.5%, specificity 88.6%), while it was 0.710 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) for the HC-VA and 0.770 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) for the 1.25% LC-VA. In discriminating between controls and ON, the AUC was also highest for the 2.5% LC-VA 0.754 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001; sensitivity 71.5%, specificity 78.5%), while it was 0.719 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) for HC-VA and 0.688 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) for 1.25% LC-VA. In eyes with a history of ON (<jats:italic>n<\/jats:italic> = 137), the HC-VA and 2.5% LC-VA were abnormal in 64.2 and 71.5%, respectively (<jats:italic>P<\/jats:italic> &amp;lt; 0.001), with their combination detecting abnormalities in approximately 85.4% (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). The 2.5% LC-VA was superior to HC-VA in detecting ON when distinguishing ON from non-ON or control. The 2.5% LC-VA might be a useful, feasible, and rapid method to detect ON. Furthermore, combining 2.5% LC-VA with conventional HC-VA would be better for detecting optic nerve involvements.<\/jats:p>","DOI":"10.3389\/fneur.2020.602193","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:18:42Z","timestamp":1608625122000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Low Contrast Visual Acuity Might Help to Detect Previous Optic Neuritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Soo-Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choul Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Joo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Sook","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/eye.2011.81","article-title":"Optic neuritis","volume":"25","author":"Pau","year":"2011","journal-title":"Eye."},{"key":"B2","unstructured":"The national eye institute visual function questionnaire: experience of the ONTT101721\n            ColeSR\n            BeckRW\n            MokePS\n            GalRL\n            LongDT\n          10752936Invest Ophthalmol Vis Sci.42000"},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/bjo.2010.193581","article-title":"Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis","volume":"96","author":"Bock","year":"2012","journal-title":"Br J Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","article-title":"Multiple sclerosis outcome assessments consortium. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis","volume":"23","author":"Balcer","year":"2017","journal-title":"Mult Scler."},{"key":"B5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/brain\/104.2.333","article-title":"Contrast sensitivity, visual acuity and the discrimination of Snellen letters in multiple sclerosis","volume":"104","author":"Regan","year":"1981","journal-title":"Brain."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1212\/WNL.0b013e3181dbb664","article-title":"Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity","volume":"74","author":"Balcer","year":"2010","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the freiburg visual acuity test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00417-014-2590-x","article-title":"Evaluation of contrast sensitivity measurements after retrobulbar optic neuritis in multiple sclerosis","volume":"252","author":"Owidzka","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B11","first-page":"2278","article-title":"Color vision defect type and spatial vision in the optic neuritis treatment trial","volume":"38","author":"Schneck","year":"1997","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1756285611398702","article-title":"Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis","volume":"4","author":"Voss","year":"2011","journal-title":"Ther Adv Neurol Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1212\/01.WNL.0000094315.19931.90","article-title":"Contrast letter acuity as a visual component for the multiple sclerosis functional composite","volume":"61","author":"Balcer","year":"2003","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jns.2012.03.009","article-title":"Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS","volume":"318","author":"Balcer","year":"2012","journal-title":"J Neurol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/WNO.0b013e318238937f","article-title":"Vision in multiple sclerosis (ms): the story, structure-function correlations, and models for neuroprotection","volume":"31","author":"Sakai","year":"2011","journal-title":"J Neuroophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awu335","article-title":"Vision and vision-related outcome measures in multiple sclerosis","volume":"138","author":"Balcer","year":"2015","journal-title":"Brain."},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1874364101206010065","article-title":"Optic neuritis, its differential diagnosis and management","volume":"6","author":"Hoorbakht","year":"2012","journal-title":"Open Ophthalmol J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies","volume":"2","author":"Galetta","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.msard.2018.01.030","article-title":"The value of tests evaluating visual functions in detecting overt or subclinical optic neuritis in multiple sclerosis","volume":"21","author":"\u00d6cek","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/135245850000600305","article-title":"New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis","volume":"6","author":"Balcer","year":"2000","journal-title":"Mult Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2016.10.009","article-title":"Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis","volume":"10","author":"Longbrake","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1212\/WNL.0b013e3181c3fd43","article-title":"Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials","volume":"73","author":"Thurtell","year":"2009","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3389\/fneur.2019.01076","article-title":"Retinal degeneration after first-ever optic neuritis helps differentiate multiple sclerosis and neurymyelitis optica spectrum disorder","volume":"10","author":"Kim","year":"2019","journal-title":"Front Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/1352458517708463","article-title":"Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis","volume":"24","author":"Balk","year":"2018","journal-title":"Mult Scler."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.602193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T08:18:59Z","timestamp":1608625139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.602193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":27,"alternative-id":["10.3389\/fneur.2020.602193"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.602193","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"article-number":"602193"}}